Positive Association Between High-Sensitivity C-reactive Protein Level and Diabetes Mellitus Among US Non-Hispanic Black Adults

Abstract

Background: Previous epidemiologic studies have demonstrated a positive association between serum C-reactive protein (CRP) level and diabetes mellitus. However among US race-ethnicities, the putative association between CRP and diabetes mellitus in non-Hispanic Blacks is not clear. We specifically examined the association between high-sensitivity CRP level and diabetes mellitus in a representative sample of US non-Hispanic blacks.

Methods: Cross-sectional study among 1,479 National Health and Nutrition Examination Survey 1999–2002 non-Hispanic black participants aged ≥20 years. Main outcome-of-interest was the presence of diabetes mellitus (fasting plasma glucose ≥126 mg/dL, non-fasting plasma glucose ≥200 mg/dL, or self-reported current use of oral hypoglycemic medication or insulin) (n=204).

Results: Higher CRP levels were positively associated with diabetes mellitus, independent of smoking, waist circumference, hypertension, and other confounders. Multivariable odds ratio (OR) [95% confidence intervals (CI)] comparing elevated CRP level (>3 mg/L) to low CRP level (<1 mg/L) was 3.12 (1.77–5.48), p-trend<0.0001. This association persisted in separate analysis among men and women. The results were consistent in subgroup analyses by categories of age, smoking, body mass index, and hypertension status. In nonparametric models, the positive association between serum CRP and diabetes mellitus appeared to be present across the full range of CRP, without any threshold effect.

Conclusions: Higher serum high-sensitivity CRP levels are positively associated with diabetes mellitus in a sample of US non-Hispanic blacks. Inflammatory processes previously shown to be related to diabetes mellitus in other race-ethnicities may be involved in non-Hispanic blacks also.

Key words

C-reactive protein - CRP - diabetes mellitus - blacks

References

• 1 Albert MA, Ridker PM. C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference?.  Circulation. 2006;  114 ((5)) e67-e74
• 2 Doi Y, Kiyohara Y, Kubo M. et al . Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study.  Diabetes Care. 2005;  28 ((10)) 2497-2500
• 3 Festa A, D’Agostino Jr R, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.  Diabetes. 2002;  51 ((4)) 1131-1137
• 4 Duncan BB, Schmidt MI, Pankow JS. et al . Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study.  Diabetes. 2003;  52 ((7)) 1799-1805
• 5 Thorand B, Lowel H, Schneider A. et al . C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998.  Arch Intern Med. 2003;  163 ((1)) 93-99
• 6 Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.  JAMA. 2001;  286 ((3)) 327-334
• 7 Barzilay JI, Abraham L, Heckbert SR. et al . The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study.  Diabetes. 2001;  50 ((10)) 2384-2389
• 8 Freeman DJ, Norrie J, Caslake MJ. et al . C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study.  Diabetes. 2002;  51 ((5)) 1596-1600
• 9 Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women.  Diabetes. 2004;  53 ((3)) 693-700
• 10 Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study.  Diabetes Care. 2002;  25 ((11)) 2016-2021
• 11 Spranger J, Kroke A, Mohlig M. et al . Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.  Diabetes. 2003;  52 ((3)) 812-817
• 12 Herder C, Peltonen M, Koenig W. et al . Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study.  Diabetes. 2006;  55 ((8)) 2340-2346
• 13 National Center for Health Statistics. .NHANES 1999–2002 Survey Questionnaires, Examination Components and Laboratory Components [article online]. Available online from: http://www cdc gov/nchs/about/major/nhanes/questexam01_02 htm [Accessed March 15 2007] 2007
• 14 National Center for Health Statistics. . NHANES 1999–2002 addendum to the NHANES III analytic guidelines [article online].  , Available online from: http://www cdc gov/nchs/data/nhanes/guidelines1 pdf , [Accessed March 15 2007] 2007
• 15 National Center for Health Statistics. . NHANES 1999-2002 Survey. C-Reactive Protein in Serum By Nephelometry [article online].  , Available online from: http://www cdc gov/nchs/data/nhanes/nhanes_01_02/l11_b_met_c_reactive_protein pdf , [Accessed March 15 2007] 2007
• 16 Pearson TA, Mensah GA, Alexander RW. et al . Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.  Circulation. 2003;  107 ((3)) 499-511
• 17 Figueiras A, Cadarso-Suarez C. Application of nonparametric models for calculating odds ratios and their confidence intervals for continuous exposures.  Am J Epidemiol. 2001;  154 ((3)) 264-275
• 18 Hastie T, Tibshirani R. Generalized additive models. 1st ed. London: Chapman and Hall 1990
• 19 Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance.  J Clin Invest. 2006;  116 ((7)) 1793-1801
• 20 Visser M, Bouter LM, MacQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults.  JAMA. 1999;  282 ((22)) 2131-2135
• 21 Das I. Raised C-reactive protein levels in serum from smokers.  Clin Chim Acta. 1985;  153 ((1)) 9-13
• 22 Schienkiewitz A, Schulze MB, Hoffmann K, Kroke A, Boeing H. Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.  Am J Clin Nutr. 2006;  84 ((2)) 427-433
• 23 Will JC, Galuska DA, Ford ES, Mokdad A, Calle EE. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study.  Int J Epidemiol. 2001;  30 ((3)) 540-546
• 24 Esposito K, Pontillo A, Di PC. et al . Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.  JAMA. 2003;  289 ((14)) 1799-1804
• 25 Manns PJ, Williams DP, Snow CM, Wander RC. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement.  Am J Hum Biol. 2003;  15 ((1)) 91-100
• 26 Tuomilehto J, Lindstrom J, Eriksson JG. et al . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 ((18)) 1343-1350
• 27 Knowler WC, Barrett-Connor E, Fowler SE. et al . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 ((6)) 393-403
• 28 Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2002;  87 ((2)) 563-568
• 29 O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus.  J Am Coll Cardiol. 1999;  33 ((6)) 1506-1511
• 30 Freeman DJ, Norrie J, Sattar N. et al . Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.  Circulation. 2001;  103 ((3)) 357-362
• 31 Yusuf S, Gerstein H, Hoogwerf B. et al . Ramipril and the development of diabetes.  JAMA. 2001;  286 ((15)) 1882-1885
• 32 Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).  Circulation. 2003;  107 ((9)) 1291-1296

Correspondence